Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma

There is no fulltext present in this item.

Title:	Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma
Author(s):	Muselaers, S.; Mulders, P.F.A. ; Oosterwijk, E. ; Oyen, W.J. ; Boerman, O.C.
Publication year:	2013
Source:	Immunotherapy, vol. 5, iss. 5, (2013), pp. 489-495
ISSN:	1750-743X
DOI:	https://doi.org/10.2217/IMT.13.36
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/118814
Display more details
Subject:	ONCOL 3: Translational research ONCOL 3: Translational research N4i 1: Pathogenesis and modulation of inflammation ONCOL 3: Translational research NCMLS 2: Immune Regulation ONCOL 3: Translational research NCMLS 3: Tissue engineering and pathology ONCOL 5: Aetiology, screening and detection ONCOL 5: Aetiology, screening and detection
Organization:	Nuclear Medicine Urology
Journal title:	Immunotherapy
Volume:	vol. 5
Issue:	iss. 5
Page start:	p. 489
Page end:	p. 495
Abstract:	Conventional imaging is suboptimal at evaluating disease status in renal cell carcinoma (RCC) because of poor sensitivity. Furthermore, there is an unmet need for the treatment of metastatic RCC, both in terms of improvement of progression-free survival and limitation of toxicity. For this reason, radionuclide imaging and radionuclide therapy are extensively investigated. This review provides an overview of the current progress in molecular imaging and radionuclide therapy in clear cell RCC and will focus on promising detection and therapy strategies targeting the carbonic anhydrase IX antigen, which is expressed in clear cell RCC.